ASIT biotech announced results from a Phase III trial of its gp-ASIT+™ treatment in grass pollen allergy (gpASIT011). The Phase III trial of gp-ASIT+™, an innovative immunotherapy treatment for grass pollen allergies which is administered in only three weeks prior to the grass pollen season, has randomized 650 patients from Belgium, Czech Republic, France, Germany, Hungary and Poland. The primary objective of the study is a 0.30 absolute reduction in the Combined Symptom and Medication Score (CSMS) in the treated group compared to placebo during the peak of the GP season. The study results showed a 0.15 (p=0.05) absolute reduction in the CSMS, during the peak of the GP season, and a 0.18 (p=0.005) absolute reduction in the CSMS during the entire GP season, translating into a treatment effect of 7.4% and 9.8% respectively vs. 20% expected.